<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004114</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067340</org_study_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-9902026</secondary_id>
    <secondary_id>NCI-G99-1603</secondary_id>
    <nct_id>NCT00004114</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer</brief_title>
  <official_title>Non-Myeloablative Chemotherapy Followed by Unrelated Allogeneic Stem Cell Transplantation in Patients With Advanced Hematologic Malignancies: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Peripheral stem cell transplantation may be able to replace
      immune cells that were destroyed by chemotherapy used to kill cancer cells.

      PURPOSE: Phase I trial to study the effectiveness of chemotherapy plus peripheral stem cell
      transplantation in treating patients who have advanced hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the feasibility of allogeneic engraftment after unrelated matched
      allogeneic peripheral blood stem cell transplantation preceded by a nonmyeloablative,
      fludarabine based conditioning regimen in patients with advanced hematologic malignancies.
      II. Determine the toxicities of this regimen, especially graft versus host disease, in these
      patients.

      OUTLINE: Patients receive fludarabine IV over 30-60 minutes on days -7 to -4,
      cyclophosphamide IV over 30 minutes on days -7 to -5, and cytarabine IV over 2 hours on days
      -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Filgrastim (G-CSF) is
      administered IV over 1 hour or subcutaneously beginning on day 1 and continuing until blood
      counts recover. Patients are followed weekly until day 60 and then monthly for 10 months.

      PROJECTED ACCRUAL: A total of 6 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never opened
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven advanced hematologic malignancy unsuitable
        for standard allogeneic bone marrow transplantation One of the following types: Refractory
        or relapsed acute myelogenous or lymphocytic leukemia Over 55 years Chronic myelogenous
        leukemia and failed interferon treatment Over 55 years Lymphoma, chronic lymphocytic
        leukemia, Hodgkin's disease, or multiple myeloma: Refractory OR More than 2 relapses OR
        Relapse after autologous peripheral blood stem cell transplantation Myelodysplastic
        syndrome other than refractory anemia Severe aplastic anemia Under 55 years and either
        organ dysfunction or not eligible for standard allogeneic bone marrow transplant due to one
        or more of the following: Chronic hepatitis LVEF less than 50% Karnofsky less than 70%
        Unrelated matched donor available

        PATIENT CHARACTERISTICS: Age: See Disease Characteristics Adult Performance status: See
        Disease Characteristics Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Not
        specified Hepatic: See Disease Characteristics SGOT/SGPT no greater than 4 times upper
        limit of normal Renal: Creatinine no greater than 2 mg/dL Cardiovascular: See Disease
        Characteristics Pulmonary: DLCO at least 50% predicted Other: Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: Not
        specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not
        specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos E. Emmanouilides, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>refractory cytopenia with multilineage dysplasia</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

